MIRA · MIRA PHARMACEUTICALS, INC.

NasdaqHealthcareDrug Manufacturers - General

Mira Pharmaceuticals Inc Is A Clinical-Stage Pharmaceutical Development Company Focused On Developing Novel Oral Small-Molecule Therapeutics For Neurologic, Neuropsychiatric, Metabolic, And Inflammatory Disorders. The Company'S Pipeline Includes Three Product Candidates: Ketamir-2, Mira-55, And Skny-1, Three Drug Candidates Designed To Address Unmet Medical Needs Across Neuropathic And Inflammatory Pain, Central Nervous System Disorders, And Metabolic And Behavioral Conditions. The Company Operates As A Single Operating And Reportable Segment.

HealthcareNasdaqUSMid Float

$2.07

+47.9% latest move

Price & move as of the most recent catalyst (Sep 15) — not a live quote.

FLOAT

29.2M

FREE FLOAT %

69%

SHARES O/S

42.0M

MARKET CAP

$29.6M

EXCHANGE

Nasdaq

COUNTRY

MIRA Catalyst History

Regulatory and ClinicalSep 15, 2025 · 4:03pm ET

Be early on the next MIRA spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

MIRA · MIRA PHARMACEUTICALS, INC.

MIRA Catalyst History

MIRA Pharmaceuticals Announces Reversal of PTSD-Like Symptoms in Animal Study

MIRA Pharmaceuticals Announces Reversal of PTSD-Like Symptoms in Animal Study

MIRA Pharmaceuticals' Ketamir-2 Demonstrates Efficacy in Animal Study for Diabetes-Associated Nerve Damage

MIRA Pharmaceuticals' Ketamir-2 Demonstrates Efficacy in Animal Study for Diabetes-Associated Nerve Damage